Global Cardiac Biomarkers Testing Market – Industry Trends and Forecast to 2030

Análisis y tamaño del mercado de pruebas de biomarcadores cardíacos

Según la Organización Mundial de la Salud, aproximadamente 4,77 millones de personas en la India padecen enfermedades cardiovasculares y la obesidad causa angina de pecho en aproximadamente el 3,1% de la población. Para reducir la carga de la enfermedad, el Gobierno de la India está poniendo en marcha una serie de iniciativas para concienciar a las zonas rurales. Varios institutos de atención sanitaria y laboratorios de diagnóstico públicos y privados están implementando kits de pruebas de diagnóstico de biomarcadores cardíacos para atender a la creciente población de pacientes.

Data Bridge Market Research analiza que el mercado de pruebas de biomarcadores cardíacos, que es de USD 12098,97 millones en 2022, se espera que alcance los USD 28491,13 millones para 2030, a una CAGR del 11,30% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de pruebas de biomarcadores cardíacos  

Definición de mercado

Los marcadores cardíacos, también conocidos como biomarcadores cardíacos, se liberan en el torrente sanguíneo cuando el corazón se estresa o sus músculos sufren daños. Estos marcadores incluyen enzimas, hormonas y proteínas como las troponinas cardíacas, la creatina quinasa (CK), la albúmina modificada por isquemia (IMA) y la mioglobina. La medición y el análisis de estos marcadores pueden ayudar en el diagnóstico de afecciones cardíacas como la isquemia cardíaca y el síndrome coronario agudo (SCA). En la actualidad, los sistemas de triaje y diagnóstico que se utilizan para determinar el riesgo de estas afecciones se basan en electrocardiogramas (ECG) y en la historia clínica.

Dinámica del mercado de pruebas de biomarcadores cardíacos

Conductores

• Aumento de la prevalencia de enfermedades cardiovasculares

Con la creciente prevalencia de enfermedades cardiovasculares, se espera que la demanda de estos kits de pruebas diagnósticas aumente en los próximos años. Según la OMS, la tasa de mortalidad por insuficiencia cardíaca está aumentando y representa más del 15,60% del total de muertes en el país. Para frenar el ritmo de aumento, el gobierno y las organizaciones de atención médica están tomando medidas preventivas para educar al público sobre los beneficios de estos kits de pruebas. Como resultado de los factores mencionados anteriormente, se espera que el mercado de pruebas de biomarcadores cardíacos crezca durante el período de pronóstico.

• Aumento de la prevalencia de enfermedades coronarias

La creciente prevalencia de la enfermedad coronaria ha aumentado el número de casos de angina de pecho/dolor torácico, en particular entre los ancianos. Según la Organización Mundial de la Salud, casi 17 millones de personas murieron por enfermedades cardiovasculares en 2019. Alrededor del 20% de ellas fueron diagnosticadas con angina de pecho. Además, a medida que los millennials consumen alimentos menos saludables, la prevalencia de la angina de pecho ha aumentado. Como resultado, se espera que aumente la demanda de pruebas de biomarcadores cardíacos para satisfacer la creciente población de pacientes.

Oportunidades

• Iniciativas gubernamentales

In the outbreak of COVID-19, governments around the world have launched a number of initiatives to improve healthcare infrastructure. Increasing healthcare spending, particularly in emerging economies such as India, South Korea, and Japan, has increased demand for advanced medical devices such as cardiac biomarkers diagnostic test kits. According to the India Brand Equity Foundation (IBEF), the Government of India approved the continuation of the "National Health Mission" in the Union Budget for 2021-22 with a budget of US$ 5.10 billion. Under this policy, the government will provide advanced medical devices in rural areas for cardiology, neurology, and other diseases in order to reduce global mortality. A slew of such initiatives around the world are expected to create market growth opportunities.

Restraints/Challenges

• Side effects associated with cardiac biomarkers

Rising side effects such as skeletal muscle injury and limited specificity in some cases will obstruct market growth and will further challenge the growth of the cardiac biomarkers testing market during the forecast period.

This cardiac biomarkers testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac biomarkers testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Roche announced the launch of five new intended uses for two key cardiac biomarkers using Elecsys technology high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These biomarkers aid in managing cardiovascular disease and can assist clinicians in diagnosing heart attacks and managing heart failure.
• In 2021, Baxter International Inc., a global leader in acute care, will collaborate with bioMérieux, a global leader in in vitro diagnostics, to launch the CE marking of the NEPHROCLEARTM CCL14 Test.

Global Cardiac Biomarkers Testing Market Scope

The cardiac biomarkers testing market is segmented on the basis of type, application and location of testing. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Myocardial muscle Creatine Kinase (CK-MB)
• Troponins (T and I)
• Myoglobin, Brain Natriuretic Peptide (BNPs)
• NT-proBNP
• Ischemia Modified Albumin (IMA)

 Application

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis

Location of Testing

• Point of Care
• Laboratory

Cardiac Biomarkers Testing Market Regional Analysis/Insights

The cardiac biomarkers testing market is analyzed and market size insights and trends are provided by country, type, application and location of testing as referenced above.

The countries covered in the cardiac biomarkers testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cardiac biomarkers testing market because of increased demand for cardiac testing, high CVD prevalence, and increased awareness of cardiac diagnostics solutions.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the region's rising modernization, rising disposable incomes, and rising affordability.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The cardiac biomarkers testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiac biomarkers testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiac biomarkers testing market. The data is available for historic period 2011-2021.

Competitive Landscape and Cardiac Biomarkers Testing Market Share Analysis

The cardiac biomarkers testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiac biomarkers testing market.

Some of the major players operating in the cardiac biomarkers testing market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• QIAGEN (Germany)
• PerkinElmer, Inc. (U.S.)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• Enzo Biochem, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Eurofins Scientific (Luxembourg)
• Agilent Technologies, Inc. (U.S.)
• Bruker (U.S.)
• Siemens (Germany)
• Epigenomics AG (Germany)
• General Electric (U.S.)

SKU-57144